Active Ingredient History

  • Now
Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics.   Wikipedia

  • SMILES: CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c4ncnc1c24
  • Mol. Mass: 400.29
  • ALogP: -1.37
  • ChEMBL Molecule:
More Chemistry
1,4,5,6,8-pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-o-phosphono-beta-d-ribofuranosyl)- | 1,4,5,6,8-pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl- | 1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl 5'-phosphate ester | 3-amino-1,5-dihydro-5-methyl-i-beta-d-ribofuranosyl-1,4,5,6,8- pentaazaacenaphthylene | 6-amino-4-methyl-8-(beta-d-ribofuranosyl)-(4h,8h)pyrrolo(4,3,2-de)pyrimido(4,5-c)pyridazine | 6-arppp | nsc 154020 | nsc-154020 | nsc 154120 | nsc 280594 | nsc-280594 | phosphate salt of tricyclic nucleoside | tcn-monophosphate | tcnp | tcn-p | triciribine | triciribine phosphate | vqd-002


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue